Low-molecular-weight heparin for prevention of thrombosis: Inverted role
Data
2007Soggetto
Abstract
BACKGROUND: Heparin induced thrombosis (HIT) after low-molecular-weight (LMWH) administration for thrombosis prevention is a limb and life threatening condition. METHODS: Two previously healthy individuals, with nonviable forearm amputation and knee osteoarthritis, suffered from multiple arterial thromboses (>2 sites each) after postoperative administration of LMWH. RESULTS: Both patients suffered from thrombocytopenia on the first postoperative days (4-7) and had signs of arterial occlusions on the 9th and 10th postoperative days. The patient with the initially successful forearm replantation was finally amputated below the elbow, whereas the lower extremity of the patient with total knee arthroplasty and contralateral femoral artery occlusion was salvaged with foot fingers amputation only. CONCLUSIONS: Early recognition of the syndrome by monitoring daily platelet counts during heparin therapy is essential. In case of postheparin (LMWH or unfractionated) platelet decrease, heparin administration should be ceased after emergency testing for heparin induced antibodies. When HIT syndrome is confirmed to have occurred, heparin/LMWH must be replaced with thrombin-specific inhibitors. © 2007 Lippincott Williams & Wilkins, Inc.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Thrombosis and Haemostasis challenges in COVID-19 – Therapeutic perspectives of heparin and tissue-type plasminogen activator and potential toxicological reactions-a mini review
Mazilu L., Katsiki N., Nikolouzakis T.K., Aslanidis M.I., Lazopoulos G., Kouretas D., Tsatsakis A., Suceveanu A.-I., Stoian A.-P., Parepa I.-R., Voinea F., Suceveanu A.P., Arsene A.L., Velescu B.Ș., Vesa C., Nitipir C. (2021)The coronavirus disease (COVID)-19 pandemic is a major challenge for the health systems worldwide. Acute respiratory distress syndrome (ARDS), is one of the most common complications of the COVID-19 infection. The activation ... -
Treatment of superficial vein thrombosis with intermediate dose of tinzaparin: A real word cohort study – The SeVEN EXTension study
Karathanos C., Chatzis D., Latzios P., Papakostas I., Goumas K., Giannoukas A.D., on behalf of the SeVEN EXT Collaborators (2021)Background: To assess the treatment of superficial vein thrombosis (SVT) with intermediate dose of tinzaparin in a setting of real world practice. Methods: Prospective observational study of consecutive patients treated ... -
New prophylaxis strategies to reduce the risk of thromboembolism in cancer
Papadopoulos V., Tsapakidis K., Markou A., Kokkalis A., Aidarinis C., Kotsakis A. (2021)Introduction: Patients with cancer are at risk of thrombotic events, mainly deep vein thrombosis and/or pulmonary embolism. The thrombosis risk is generally 4–6 times higher than in a healthy population and depends on ...